泰莫佐洛米德纳米在纳米纤维的输送系统具有持续释放和增强的细胞吸收由U87MG细胞
Karishma Shetty1, Khushwant S Yadav1
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India.
Drug development and industrial pharmacy
|March 19, 2024
概括
这项研究开发了用于质母细胞瘤治疗的聚乙烯醇纳米纤维中含有temozolomide的凝纳米颗粒. 在实验室中,纳米在纳米纤维系统证明了持续的药物释放和显著增强的细胞吸收.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 纳米在纳米纤维系统代表了药物输送的先进方法,解决了独立纳米颗粒和纳米纤维的局限性.
- 这些系统为治疗癌症等复杂疾病提供了潜在的优势.
研究的目的:
- 在聚乙烯醇 (PVA) 纳米纤维 (TMZ-GNPs-PVA NFs) 中封装的含有temozolomide (TMZ) 的凝纳米颗粒 (GNPs) 的配方.
- 评估纳米-在-纳米纤维系统的持续药物释放能力.
- 为了在体外评估该配方对U87MG质瘤细胞的增强细胞吸收.
主要方法:
- 装载着temozolomide的凝纳米颗粒使用一步溶解方法进行了准备.
- 使用实验设计 (DoE) 方法来优化纳米粒子大小和捕获效率.
- 优化的纳米颗粒通过混合电回旋被封装到PVA纳米纤维中.
主要成果:
- 优化的TMZ装载GNP实现了平均粒子大小为145.7nm和捕获效率为87.6%.
- 纳米-在-纳米纤维系统表现出持续的药物释放长达七天.
- 与纯药物相比,U87MG结质瘤细胞对TMZ-GNPs-PVA NFs的细胞吸收是1.964倍.
结论:
- 开发的纳米-在-纳米纤维药物输送系统显示了质母细胞瘤多种形式管理的前景.
- 这个系统为脑瘤提供了一个潜在的有效治疗策略.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:18Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233